im

After three lost glyphosate-cancer trials, Bayer investors fear litigation ‘avalanche’ will further harm company’s reputation

Bloomberg |
Two influential shareholder advisory groups are split on whether investors should support Bayer AG’s management at its upcoming annual meeting, ...